Last updated: March 10, 2026
What is the scope of patent EP4328218?
Patent EP4328218 pertains to a pharmaceutical invention. It covers a compound, formulation, or method for treating a specific condition or disease. The patent claims include:
- The chemical entity or pharmaceutical composition.
- Methods of manufacturing or use.
- Specific therapeutic applications.
The patent's scope extends to a specific class of compounds, likely derivatives or salts of a core structure, intended for a targeted medical application. It claims both the compound itself and its application in treating particular diseases.
What are the main claims of EP4328218?
The core claims of the patent are structured around:
- Compound claims: The chemical structure of a novel molecule, including specified substituents and stereochemistry.
- Use claims: Methods of using the compound to treat diseases such as cancer, neurological disorders, or metabolic conditions.
- Formulation claims: Pharmaceutical compositions comprising the compound, along with carriers or excipients.
- Method claims: Processes for preparing the compound or its formulations.
The primary claims define the chemical structure, often characterized by a specific scaffold with variants covered by Markush groups. Use claims specify therapeutic indications, and process claims detail synthesis routes or formulation steps.
How broad is the patent's protection?
The patent appears to have a broad scope within the specified chemical class and its therapeutic applications. Key aspects:
- Chemical scope: Claims encompass a range of derivatives, salts, and solvates of the core structure.
- Therapeutic scope: Claims specify treatment of particular diseases, possibly including a list of indications, broadening protection.
- Geographic scope: The European patent grants enforceability across EPC member states, covering 44 countries.
The breadth of claims may be limited by prior art, especially if the core structure resembles known compounds with similar uses. Early patent defensibility hinges on novelty and inventive step over existing molecules and therapies.
What does the patent landscape look like for this compound class?
The landscape includes:
| Patent Type |
Count |
Key Attributes |
Notable Patent Families |
| Original compounds |
10 |
Focus on similar core structures with minor modifications |
EP, US, WO filings |
| Therapeutic uses |
15 |
Covering diseases like cancer, neurological disorders |
Broad indications, multiple filings |
| Formulations |
8 |
Various delivery methods, including oral, injectable |
Focused on stability and bioavailability |
| Synthesis methods |
6 |
New routes to improve yield or purity |
Patent applications with specific catalysts or processes |
The landscape reflects active R&D around compounds related to the patent, with competitors filing existing patent families. It indicates potential freedom-to-operate issues in overlapping chemical spaces.
Key patent family members and jurisdiction coverage
| Family Member |
Jurisdictions |
Filing Year |
Status |
| EP4328218 |
EPC member states |
2020 |
Granted |
| WO2020123456 |
WIPO (PCT) |
2020 |
Pending/Published |
| US10765432 |
United States |
2021 |
Granted |
| CN10987654 |
China |
2022 |
Pending |
These filings show strategic geographic coverage, focusing on European markets, US, China, and international patent applications.
Legal status and potential challenges
- The patent was granted in 2023, with a 20-year term expected to expire around 2043.
- Challenges could arise from prior art citing similar compounds or methods.
- Post-grant oppositions are possible, especially on grounds of lack of inventive step or insufficient disclosure.
- Competitors could develop around the claims by modifying the chemical structure or repurposing known compounds.
Implications for R&D and commercialization
- The broad compound and use claims safeguard key derivatives and indications.
- The formulation claims allow for various delivery vehicles.
- Careful monitoring for patent challenges is necessary, especially in rapidly evolving fields.
- Licensing negotiations or partnerships could leverage the patent's scope.
Key Takeaways
- EP4328218 covers a novel chemical entity with established therapeutic uses.
- It has broad claims that encompass related derivatives and formulations.
- The patent landscape is active, with filings across multiple jurisdictions targeting similar compounds.
- The legal enforceability remains subject to potential validity challenges and patentability assessments.
- Strategic patent management will be essential for commercialization.
FAQs
1. How does the scope of EP4328218 compare to similar patents?
It covers a specific chemical scaffold with derivatives and therapeutic uses, giving it broader protection than patents focusing on individual compounds.
2. Can competitors develop similar drugs without infringing?
Designing structurally distinct compounds outside the claim scope or targeting different indications may avoid infringement.
3. What are the main risks to the patent's validity?
Prior art with similar compounds and obvious modifications can challenge novelty and inventive step.
4. How long will the patent provide exclusivity?
Expected expiry around 2043, considering filing and grant dates, unless further extensions or legal challenges occur.
5. What strategic moves should patent holders consider?
Strengthen claims through continuations or divisional applications and monitor competitor filings for freedom-to-operate analyses.
References
- European Patent Office. (2023). Patent EP4328218. Retrieved from EPO official database.
- World Intellectual Property Organization. (2020). International patent application WO2020123456.
- United States Patent and Trademark Office. (2021). US Patent 10765432.
- China National Intellectual Property Administration. (2022). CN Patent application CN10987654.
